Express News | Shanghai aims to nurture around 10 internationally competitive listed companies in key industries such as integrated circuits, biomedical, and new materials by 2027, forming a merger and acquisition trade scale of 300 billion yuan.

BreakingsDec 10 15:15

The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!

Industry pessimistic expectations may improve.

Gelonghui FinanceDec 9 12:10

How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.

① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.

cls.cnDec 8 16:48

Yum China (09987.HK) repurchased on the nyse and Hong Kong Stock Exchange this Tuesday.

Yum China (09987.HK)(YUMC.US) announced that on Tuesday of this week (3rd), it repurchased 0.0509 million shares on the New York Stock Exchange at a repurchase price ranging from $46.81 to $47.33 per share, with a total consideration of $2.3999 million. In addition, on the same day, the company repurchased 0.0128 million shares on the Stock Exchange of Hong Kong at a repurchase price ranging from 362.6 to 369 yuan per share, involving 4.6857 million yuan. (js/k)~

AASTOCKSDec 5 09:19

Fosun Pharma (02196.HK) has received approval to conduct clinical trials for cancer treatment drugs in mainland China.

Fosun Pharma (02196.HK) announced that its holding subsidiary Shanghai Henlius Biotech and its subsidiaries (collectively referred to as "Henlius") have recently received approval from the National Medical Products Administration for conducting clinical trials on HLX22 in combination with trastuzumab and chemotherapy, or in combination with deruxtecan for treating HER2-expressing solid tumors. Henlius plans to conduct the Phase II clinical trial of this new drug in China once conditions are met. Fosun Pharma stated that HLX22 involved in these treatment regimens is a novel targeted HER2 developed independently by the group through licensing from AbClon, Inc.

AASTOCKSDec 5 08:56

Hong Kong stocks early report on December 5: Most china concept stocks declined, Meitu cleared cryptocurrency profits of about 0.571 billion yuan.

① The latest Beige Book survey by the Federal Reserve shows a slight increase in economic activity in November. ② Powell said the Federal Reserve can be cautious when seeking a neutral interest rate. ③ Trump chose digital assets advocate Paul Atkins to be the chairman of the U.S. Securities and Exchange Commission, leading to a big surge in cryptos and their concept stocks. ④ The three major U.S. stock indexes hit new all-time highs on Wednesday, while most popular China concept stocks declined.

cls.cnDec 5 07:15